Insulet | PODD - Ebitda

Aktienkurs
189.56
Täglich Wechseln
-2.65 -1.38%
Monatlich
-12.24%
Jährlich
-27.29%
Q2 Prognose
185.50




Ebitda Veränderung Datum
Abbott USD 3.27B 178M 2025-12
Align Technology USD 183.84M 19.77M 2025-09
AtriCure USD 19.86M 2.06M 2025-12
Avanos Medical USD 10M 73.9M 2025-09
Baxter International USD 426M 36M 2025-09
Becton, Dickinson and Co. USD 1.71B 433M 2025-12
Boston Scientific USD 1.16B 213M 2025-12
Cardinal Health USD 981M 5M 2025-12
Cooper Companies USD 323.4M 13.2M 2025-12
Dexcom USD 422.2M 53.8M 2025-12
Edwards Lifesciences USD 70.1M 394.2M 2025-12
Eli Lilly USD 7.88B 378.1M 2025-09
Globus Medical USD 280.46M 27.86M 2025-12
ICU Medical USD 98.19M 27.67M 2025-12
Insulet USD 194M 34M 2025-12
Integra LifeSciences USD 104.21M 25.76M 2025-12
J&J USD 7.19B 2.32B 2025-12
Masimo USD 91.9M 19.9M 2025-09
Medtronic USD 2.93B 482M 2025-12
Merit Medical Systems USD 97.23M 17.69M 2025-12
Roche Holding CHF 12.68B 2.36B 2024-06
Solventum Corp USD 437M 38M 2025-12
Stryker USD 1.67B 206M 2025-09
Tandem Diabetes Care USD 32.9M 30.13M 2025-12
Teleflex USD -328.81M 536.43M 2025-09
West Pharmaceutical Services USD 226.2M 7.7M 2026-03
Zimmer Biomet Holdings USD 759M 120.8M 2025-12